The Section 18 emergency approval itself is limited: It allows only the Texas Department of Agriculture to approve use of SurfaceWise2 in the state by American Airlines in certain airport facilities and aircraft and also by two Total Orthopedics Sports & Spine Clinics affiliated with Texas Methodist Health Group. The emergency exemption is effective for one year. EPA indicated that it will be accepting other FIFRA Section 18 emergency exemption applications for the same or similar long-lasting efficacy products, although such applications may only be made by state or federal agencies.
Currently, there are no other publicly available long-lasting efficacy products registered with EPA for antiviral efficacy. EPA indicated in its Monday announcement that it anticipates publishing in coming weeks testing guidelines and other guidance for companies and individuals interested in pursuing full FIFRA registration of antiviral long-lasting efficacy products beyond the limited emergency exemption pathway. If registered for effectiveness against viruses similar to the novel coronavirus or SARS-CoV-2 itself, the long-lasting efficacy product would likely be added to EPA’s List N and would be available for use by the general public on surfaces for the contact time and residual efficacy period approved on the product labeling. EPA watchers are also looking intently for whether the Agency will approve any products for use to combat the novel coronavirus in airborne virus particles, the primary mode of communication. As of yet, the Agency has not approved such products.
EPA’s announcement of this emergency exemption approval coincides with an upcoming webinar on Thursday, August 27, titled “COVID-19 Long Lasting Disinfectants” to be presented by EPA research scientists from the agency’s Center for Environmental Solutions and Emergency Response. Our expectation is that the federal regulatory landscape for surface disinfectants will continue to evolve in the coming month as EPA continues to adapt the historically slow-moving FIFRA regime in an ongoing response to the COVID-19 pandemic.
Sidley Austin LLPはクライアントおよびその他関係者へのサービスの一環として本情報を教育上の目的に限定して提供します。本情報をリーガルアドバイスとして解釈または依拠したり、弁護士・顧客間の関係を結ぶために使用することはできません。
弁護士広告 - ニューヨーク州弁護士会規則の遵守のための当法律事務所の本店所在地は、Sidley Austin LLP ニューヨーク：787 Seventh Avenue, New York, NY 10019 (+212 839 5300)、シカゴ：One South Dearborn, Chicago, IL 60603、(+312 853 7000)、ワシントン：1501 K Street, N.W., Washington, D.C. 20005 (+202 736 8000)です。
